The 9 most recent market catalysts affecting $CLLS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Bearish
Impact 85
Cellectis shares are trading lower after Barclays downgraded the stock from Overweight to Underweight rating and lowered its price target from $9 to $1.3.
This downgrade represents a significant corporate catalyst for Cellectis, as a major investment bank like Barclays shifting from 'Overweight' to 'Underweight' with such a drastic p…
Sep 16, 2026
Corporate Catalyst
Bearish
Impact 75
Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3
Barclays analyst Lukas Shumway has issued a significant downgrade for Cellectis (CLLS), moving it from an 'Overweight' to an 'Underweight' rating and drastically cutting the price …
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 75
Cellectis shares are trading lower after Baird and Wells Fargo lowered their respective price targets on the stock.
The lowered price targets from Baird and Wells Fargo are a significant negative catalyst for Cellectis. This action by reputable financial institutions signals a potential downgrad…
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 65
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
The filing highlights multiple analyst downgrades across different companies and sectors. This matters because analyst ratings often influence investor sentiment and can lead to sh…
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 55
Baird Maintains Outperform on Cellectis, Lowers Price Target to $8
Baird analyst Jack Allen maintained an 'Outperform' rating on Cellectis but lowered the price target from $10 to $8. This action signals that while the analyst still sees potential…
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 55
Citizens Downgrades Cellectis to Market Perform
Citizens analyst Silvan Turkcan downgraded Cellectis (CLLS) from Market Outperform to Market Perform. This action indicates a less optimistic view on the company's prospects, likel…
Sep 14, 2026
Market Technicals
Bearish
Impact 65
Nasdaq Down Over 200 Points; Cellectis Shares Plunge
The filing details a general market decline on Monday, with the Nasdaq Composite falling over 200 points and the S&P 500 and Dow also down. This indicates a broad-based negative se…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 95
Cellectis Pivots to Gene Editing in Major Overhaul
Cellectis is undergoing a significant strategic overhaul, abandoning its allogeneic CAR T-cell programs (lasme-cel and eti-cel) to focus entirely on in vivo gene editing. This deci…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 92
Cellectis Q2 Adj. EPS $(0.19) Beats $(0.27) Estimate, Sales $6.904M Miss $13.225M Estimate
Cellectis' Q2 earnings report presents a mixed picture, with a beat on adjusted EPS but a substantial miss on sales. The EPS beat, while positive, is overshadowed by the 47.80% sal…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.